Metabolic consequences of hyperglycemia and insulin resistance

Danaei, 2006, Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment, Lancet, 368, 1651, 10.1016/S0140-6736(06)69700-6 Lawes, 2004, et al, Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care, 27, 2836 Brownlee, 2005, The pathobiology of diabetic complications: A unifying mechanism, Diabetes, 54, 1615, 10.2337/diabetes.54.6.1615 Cryer, 2005, Hypoglycemia, 2180 Yki-Jarvinen, 2003, Nonglycemic effects of insulin, Clin Cornerstone, 2003, S6, 10.1016/S1098-3597(03)90061-5 Eckel, 2005, Zimmet PZ, The metabolic syndrome. Lancet, 365, 1415 Montagnani, 2002, Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells, Mol Endocrinol, 16, 1931, 10.1210/me.2002-0074 Trovati, 1998, Insulin, insulin resistance and platelet function: Similarities with insulin effects on cultured vascular smooth muscle cells, Diabetologia, 41, 609, 10.1007/s001250050958 Juhan-Vague, 1996, Vague R Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin dependent diabetes mellitus, Ann Med, 28, 371, 10.3109/07853899608999095 Feener, 1997, King GL, Vascular dysfunction in diabetes mellitus. Lancet, 350, S9 McFarlane, 2001, Sowers JR, Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab, 86, 713 Guyton, 2006, Insulin, glucagon, and diabetes mellitus, 961 Dandona, 2004, Inflammation: The link between insulin resistance obesity and diabetes, Trends Immunol, 25, 4, 10.1016/j.it.2003.10.013 Furnary, 2006, Wu Y, Clinical effects of hyperglycemia in the cardiac surgery population: The Portland Diabetic Project. Endocr Pract, 12, 22 Du, 2006, et al, Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest, 116, 1071 Kawano, 1999, et al, Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol, 34, 146 Miranda, 2005, Metabolic syndrome: Definition, pathophysiology and mechanisms, Am Heart J, 149, 33, 10.1016/j.ahj.2004.07.013 Avramoglu, 2006, Adeli K, Lipid and lipoprorein dysregulation in insulin resistant states. Clin Chim Acta, 368, 1 Abrahamson, 2007, A 74-year-old woman with diabetes, N Engl J Med, 297, 196 Boden, 2004, Laakso M, Lipids and glucose in type 2 diabetes: What is the cause and effect? Diabetes Care, 27, 2253 Boden, 1991, et al, Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest, 88, 960 Homko, 2003, Boden G, Effects of free fatty acids on glucose uptake and utilization in healthy women. Diabetes, 52, 487 Ceriello, 2000, Oxidative stress and glycemic regulation, Metabolism, 49, 27, 10.1016/S0026-0495(00)80082-7 Itani, 2002, Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha, Diabetes, 51, 2005, 10.2337/diabetes.51.7.2005 Fonseca, 2004, Jialal I, Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev, 25, 153 Meigs, 2000, Hyper-insulinemia, hyperglycemia and impaired hemostasis: The Framingham Offspring Study, JAMA, 283, 221, 10.1001/jama.283.2.221 Grundy, 2004, Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Cirulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6 Shoelson, 2006, Goldfine AB, Inflammation and insulin resistance. J Clin Invest, 116, 1793, 10.1172/JCI29069 Hotamisligil, 1993, Spiegelman BM, Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science, 259, 87 Feinstein, 1993, et al, Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem, 268, 26055 Reaven, 2004, The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals, Endocrinol Metab Clin North Am, 33, 283, 10.1016/j.ecl.2004.03.002 Nishikawa, 2000, et al, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404, 787 Du, 2003, et al, Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest, 112, 1049 Schmidt, 1995, et al, 96, 1395 Schmidt, 1999, Stern D, Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Cire Res, 84, 489 Tripathy, 2003, et al, Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes, 52, 2882 Anderson, 1991, et al, Hyper-insulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest, 87, 2246 Lewis, 1995, et al, Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest, 95, 158 Brinton, 1991, Breslow JL, Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest, 87, 536 de Graaf, 1993, Stalenhoef AE Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects, Normalization after clofibrate treatment. Arterioscler Thromb, 13, 712, 10.1161/01.ATV.13.5.712 Carroll, 2004, Dudfield M, What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med, 34, 371 Palomo, 2006, Argiles JM, Hemostasis alterations in metabolic syndrome (review). Int J Mol Med, 18, 969 Govindarajan, 2005, et al, The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci, 330, 311 Stump, 2005, Sowers JR, Oxidative stress in insulin-resistant conditions: Cardiovascular implications. Treat Endocrinol, 4, 343 Inzucchi, 1998, et al, Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 338, 867 Hundal, 2003, Metformin: New understandings new uses, Drugs, 63, 1879, 10.2165/00003495-200363180-00001 Palamara, 2006, Obesity: New perspectives and pharmacotherapies, Cardiol Rev, 14, 238, 10.1097/01.crd.0000233903.57946.fd Rains, 1989, Elkeles RS, The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med, 82, 93 DeFronzo, 1995, Goodman AM, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med, 333, 541 Reaven, 1992, et al, Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab, 74, 1020 Giugliano, 1993, Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women, Diabetes Care, 16, 1387, 10.2337/diacare.16.10.1387 Fonseca, 2000, Salzman A, Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA, 283, 1695 Misbin, 1977, Phenformin-associated lactic acidosis: Pathogenesis and treatment, Ann Intern Med, 87, 591, 10.7326/0003-4819-87-5-591 Luft, 1978, Eggstein M, Lactic acidosis in biguanide-treated diabetics: A review of 330 cases. Diabetologia, 14, 75 Goodarzi, 2005, Bryer-Ash M, Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab, 7, 654 Garg, 2000, et al, Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension, 36, 430 Aljada, 2001, et al, Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: Evidence of an antiinflammatory action? J Clin Endocrinol Metab, 86, 3250 Ghanim, 2001, et al, Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab, 86, 1306 Fonseca, 1998, et al, Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications, 12, 181 Parulkar, 2001, et al, Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med, 134, 61, 10.7326/0003-4819-134-1-200101020-00014 Haffner, 2002, et al, Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Cireulation, 106, 679 Promrat, 2004, et al, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 39, 188 Nissen, 2007, Wolski K, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 356, 1304 Gadde, 2006, Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks, Cireulation, 114, 974, 10.1161/CIRCULATIONAHA.105.596130 Matsuda, 1990, et al, Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561 Spanagel, 1999, Weiss E The dopamine hypothesis of reward: Past and current status, Trends Neurosci, 22, 521, 10.1016/S0166-2236(99)01447-2 Cohen, 2002, SR141716, a central cannabinoid (CB(1)) receptor antagonist blocks the motivational and dopamine-releasing effects of nicotine in rats, Behav Pharmacol, 13, 451, 10.1097/00008877-200209000-00018 Colombo, 1998, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716, Life Sci, 63, PL113, 10.1016/S0024-3205(98)00322-1 Vickers, 2003, Preferential effects of the cannabinoid CB 1 receptor antagonist, SR 141716 on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats, Psychopharmacology (Berl), 167, 103, 10.1007/s00213-002-1384-8 Arnone, 1997, et al, Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.Psychopharmacology (Berl), 132, 104 Simiand, 1998, SR 141716, a CB 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset, Behav Pharmacol, 9, 179 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 Scheen, 2006, Efficacy and toterability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study, Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8